Vycor Medical earnings release, August 14, 2026

Vycor Medical Inc (VYCO) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Vycor

Medical Releases Financial Results for the Three And Six Months Ended June 30, 2026

BOCA

RATON, FL (August 14, 2026) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the three and six months ended June 30, 2026.

The

Company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgeons; and NovaVision®, a business in development which offers therapy programs to help patients recover from visual disorders after stroke or other brain injury.

Company

Highlights

Financial

Results

For the three months ended June 30, 2026, the Company reported revenue of $418,264, a decrease of 16% over the 2025 period. The Vycor Medical division (VBAS) generated revenue of $401,224, a decrease of $80,564 (or 17%) over the 2025 period, with most of the decrease from international markets. Gross profit for 2026 was $327,225, a 19% decrease over

2025, generating a margin of 82% and 83%, respectively. The NovaVision division, which remains in development, generated revenues of $17,040 for the three months ended June 30, 2026, a 17% increase over the

2025 period.

For the six months ended June 30, 2026, the Company reported revenue of $876,804, a decrease of 6% over the 2025 period. The Vycor Medical division (VBAS) generated revenue of $841,665, a decrease of $58,643 (or

7%) over the 2025 period, the decrease equally split between US and international markets. Gross profit for 2026 was

$686,265, an 8% decrease over 2025, generating a margin of 82% and 83%, respectively. The NovaVision division, which remains in development, generated revenues of $35,139 for the three months ended

June 30, 2026, an 8% increase over the 2025 period.

For the three months ended June 30, 2026 the Company reported non-GAAP Cash Operating Expenses of $321,492 compared to $329,559 in the 2025 period, and non-GAAP Operating Profit of $22,952 compared to $85,712 in the 2025 period. For the six months ended June 30, 2026 the Company reported non-GAAP Cash Operating Expenses of $636,858 compared to $667,705 in the 2025 period, and non-GAAP Operating Profit of $82,740 compared to $106,100 in the 2025 period.

Reconciliation of Non-GAAP Information

Non-GAAP

Reconciliation

Management uses certain non-GAAP financial measures (including non-GAAP operating expenses and non-GAAP net loss and loss per share), which exclude non-cash depreciation of purchased assets and non-cash stock-based compensation. Management does not consider these costs in evaluating the continuing operations of the Company. Therefore, management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non-GAAP financial measures to enable it to analyze further, and more consistently, the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP measures gives them additional important information to enable them to assess, in the same way management assesses, the Company’s current and future continuing operations. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company’s consolidated financial statements prepared in accordance with

GAAP. Set forth below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measures.

Three months ended June 30, 2026

On a GAAP basis for three months ended June 30, 2026 the Company reported Operating Expenses of

$337,594, an operating profit of

$6,851, a net loss of $(22,288) or $(0.00 per share.

Vycor’s

GAAP operating costs for three months ended June 30, 2026 include non-cash depreciation of purchased assets ($16,101). The Company is providing additional non-GAAP financial measures that exclude these charges and expenses, and reconciliation of GAAP to non-GAAP results is provided in the tables included in this release.

On a non-GAAP basis, taking into account these adjustments, operating expenses for the three months ended June 30, 2026 were $321,492, non-GAAP operating profit was $22,952, and non-GAAP net loss was $(6,187) or $(0.00) per share.

Six months ended June 30, 2026

On a GAAP basis for six months ended June 30, 2026 the Company reported Operating Expenses of $666,939, an operating profit of $52,659, a net loss of $(164,365) or

$(0.00) per share.

Vycor’s

GAAP operating costs for six months ended June 30, 2026 include non-cash depreciation of purchased assets ($30,081). The Company is providing additional non-GAAP financial measures that exclude these charges and expenses, and reconciliation of GAAP to non-GAAP results is provided in the tables included in this release.

On a non-GAAP basis, taking into account these adjustments, operating expenses for the six months ended June 30, 2026 were $636,858, non-GAAP operating profit was $82,740, and non-GAAP net loss was $(134,284) or $(0.00) per share.

VYCOR

MEDICAL, INC.

Consolidated Statements of Comprehensive Loss

(audited)

VYCOR

MEDICAL, INC.

Non-GAAP Reconciliation of Operating Loss and Net Loss

(unaudited)

(1)

Non-Cash depreciation of purchased assets.

These are non-cash charges related to assets which can be impacted by the timing and magnitude of acquisitions. We consider our operating results without these charges when evaluating our ongoing costs and performance and therefore exclude such charges when presenting non-GAAP financial measures...

Non-Cash Stock-based compensation expense consists of expense relating to stock-based compensation issued to employees, outside directors and non-employees including stock options, restricted common stock, and warrants. Because of varying available valuation methodologies, subjective assumptions and the fact that these amounts vary in size and timing, we believe that the exclusion of stock-based compensation expense allows for a more accurate comparison of our financial results to previous periods. In addition, we believe it is useful to investors to understand the specific impact of stock-based compensation expenses on our operating results.

About

Vycor Medical, Inc.

With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (“Vycor”) is a publicly traded company (OTCQB: VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared or registered medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor

Medical and NovaVision, both of which adopt a minimally or non-invasive approach.

Vycor

Medical’s FDA-cleared ViewSite™ Brain Access System (VBAS) a minimally invasive neurosurgical device designed to improve access to brain lesions while reducing tissue damage and enhancing patient outcomes. The VBAS system has been approved and used in over

350 hospitals in the US and in numerous countries internationally. VBAS is protected by 49 issued and 8 pending patents and has been validated through over 50 peer-reviewed studies. These studies demonstrate that use of VBAS results in: less brain tissue damage; less invasive procedure; improved access and better visibility; and reduced operating and recovery time. For an overview of Vycor Medical’s

VBAS see

VBAS Video.

NovaVision provides a suite of clinically supported vision rehabilitation therapies aimed at helping patients recover from visual impairments caused by stroke or other brain injury. The Visual Restoration Therapy (VRT) is the only commercialized FDA-cleared therapy for vision rehabilitation following neurological brain damage, making it a unique and important option for patients seeking to regain lost visual capabilities.

The complementary NeuroEyeCoach program, clinically supported by a 296-patient study (the largest to date in the neuro visual space), enables dramatic improvements in patients’ ability to detect objects in the visual field by training them to make better eye movements with improvement in over 80% of patients. The NovaVision therapies, while showing a positive impact on these patients’ lives, still require significant development to allow them to successfully address their market potential. For an overview of NovaVision see

NovaVision

Video.

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com, www.vycorvbas.com or www.novavision.com.

Safe

Harbor Statement

Financial statements

Income Statement

Three months ended June 30,

Three months ended June 30, – 2026Three months ended June 30, – 2025Six months ended June 30, – 2026Six months ended June 30, – 2025
RevenueVycor Medical401,224481,788841,665900,308
RevenueNovaVision17,04014,56535,13932,423
Revenue418,264496,353876,804932,731
Gross ProfitVycor Medical327,225401,783686,265743,581
Gross ProfitNovaVision17,22013,48833,33330,224
Gross Profit344,445415,271719,598773,805

Income Statement

For the three months ended June, 30 — VYCOR MEDICAL, INC. Consolidated Statements of Comprehensive Loss (audited)

For the three months ended June, 30 – 2026For the three months ended June, 30 – 2025For the six months ended June, 30 – 2026For the six months ended June, 30 – 2025
Revenue418,264496,353876,804932,731
Cost of Goods Sold73,81981,082157,206158,926
Gross Profit344,445415,271719,598773,805
Operating Expenses:Research and development4,2019,963
Operating Expenses:Depreciation and amortization14,88314,88128,86329,761
Operating Expenses:Selling, general and administrative322,711345,043638,076695,741
Operating Expenses:Total Operating Expenses337,594364,125666,939735,465
Operating Expenses:Operating income6,85151,14652,65938,340
Other (Expense) IncomeInterest expense: Related Party-12,570-12,572-25,140-25,142
Other (Expense) IncomeInterest expense: Other-13,264-12,862-26,403-26,001
Other (Expense) Income(Loss) gain on foreign currency exchange-1261-1302
Other (Expense) IncomeTotal Other (Expense)-25,960-25,433-51,673-51,141
Other (Expense) IncomeIncome (Loss) Before Provision for Income Taxes-19,10925,713986-12,801
Other (Expense) IncomeNet Income (Loss) from continuing operations-19,10925,713986-12,801
Other (Expense) IncomeLoss from discontinued operations, net of tax-3,179-1,826-3,166-1,875
Other (Expense) IncomeNet Income (Loss)-22,28823,887-2,180-14,676
Other (Expense) IncomePreferred stock dividends-162,185-162,185
Other (Expense) IncomeNet Loss Available to Common Stockholders-22,28823,887-164,365176,861
Other Comprehensive Income (Loss)Foreign Currency Translation Adjustment-20-20
Other Comprehensive Income (Loss)Comprehensive Income (Loss)-22,30823,887-2,20014,676
Income (Loss) Per Share - basic and dilutedIncome (Loss) from continuing operations0000.01
Income (Loss) Per Share - basic and dilutedLoss from discontinued operations0000
Income (Loss) Per Share - basic and dilutedIncome (Loss) available to common stockholders0000.01
Income (Loss) Per Share - basic and dilutedWeighted Average Number of Shares Outstanding – Basic and Diluted33,372,79633,372,79633,372,79633,372,796
Income (Loss) Per Share - basic and dilutedWeighted Average Number of Shares Outstanding – Diluted33,372,79638,667,86233,372,79633,372,796

Income Statement

For the three months ended June 30, — VYCOR MEDICAL, INC. Non-GAAP Reconciliation of Operating Loss and Net Loss (unaudited)

For the three months ended June 30, – 2026For the three months ended June 30, – 2025For the six months ended June 30, – 2026For the six months ended June 30, – 2025
GAAP Operating Expenses337,593364,125666,939735,465
Non-cash depreciation of purchased assets (1)-16,101-16,251-30,081-31,131
Non-cash stock-based compensation (2)-18,315-36,629
Total Non-GAAP Operating Expense Adjustments-16,101-34,566-30,081-67,760
Non GAAP Cash Operating Expenses321,492329,559636,858667,705
GAAP Operating Profit6,85151,14652,65938,340
Non-GAAP Operating Expense Adjustments, as above16,10134,56630,08167,760
Non-GAAP Operating Profit22,95285,71282,740106,100
GAAP Net Income (Loss) available to common shareholders-22,28823,887-164,365-176,861
Non-GAAP Operating Expense Adjustments, as above16,10134,56630,08167,760
Non-GAAP Net Income (Loss) available to common stockholders-6,18758,453-134,284-109,101
Non-GAAP Income (Loss) Per Share basic and diluted0000
Weighted Average Number of Shares Outstanding – Basic33,372,79633,372,79633,372,79633,372,796
Weighted Average Number of Shares Outstanding – Diluted33,372,79638,667,86233,372,79633,372,796
Full release

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “forecast”, “anticipate”,

“estimate”, “project”, “intend”, “expect”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

Vycor

Medical, Inc. Contacts:

951

Broken Sound Parkway, Suite 320

Boca

Raton, FL. 33487

(561)

558-2020 info@vycormedical.com

LinkedIn: https://www.linkedin.com/in/vycor-medical-inc/

Instagram: https://www.instagram.com/vycormedical/

Facebook: https://www.facebook.com/Vycor.Nova/

Twitter/X: https://x.com/vycormedical

YouTube: https://www.youtube.com/@vycormedical6049

##END##

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.